Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ABVEW vs CDT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABVEW Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 2–6 Matrix Metrics)

ABVEW Overall Winner 6-Pillar Tally: ABVEW 2 – 2 CDT (2 Tie) Matrix Metrics: ABVEW 2 – 6 CDT

As of Nov 20, 2026, Above Food Ingredients Inc. Warrants (ABVEW) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ABVEW carries a Unified Composite Score of 37.2/100 (SELL) at $0.02 (N/M Forward P/E, N/A operating margin), whereas CDT carries 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although ABVEW compares more favorably head-to-head, both ABVEW (37.2/100 SELL) and CDT (31.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: ABVEW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2); meanwhile CDT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABVEW vs CDT
ABVEW NASDAQ Head-to-Head Winner
Above Food Ingredients Inc. Warrants
Institutional Equity
$0.02
-86.37% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.07β · 408% Vol
Unified Composite Score
37.2 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 53.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.3%), weak momentum, RSI 32
RSI-14: 32.2 · SMA20: $0.15 · SMA50: $0.19
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -17.75β · 10175% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -58.9%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $0.31 · SMA50: $0.40

6-Pillar Scorecard Institutional Category Breakdown (ABVEW 2 – 2 CDT)

Columns: Metric · ABVEW · CDT
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CDT
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $507,528
3. Profitability & Quality CDT
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -69.7%
4. Balance Sheet & Cash Flow ABVEW
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $435,000 Net Debt (0.01x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABVEW
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABVEW (2) vs CDT (6)
Institutional Metric ABVEW CDT Criterion Row Edge
Market Capitalization
Scale
N/A $507,528 Larger Scale CDT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth CDT
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin CDT
Net Profit Margin
Profitability
N/A 0.0% Higher Margin CDT
Return on Equity (ROE)
Capital Efficiency
N/A -69.7% Higher ROE CDT
52-Week Range Position
Momentum
0% ($0–$2) 2% ($0–$11) Stronger Trend CDT
Beta / 30D Volatility
Risk Regime
4.07β · 408% Vol -17.75β · 10175% Vol Lower Realized Risk ABVEW
Unified Institutional Score
Composite Signal
37.2 / 100 (SELL) 31.6 / 100 (SELL) Higher Composite ABVEW
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A ($435,000 Net Debt (0.01x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDT +25.63 pp
ABVEW: -87.14% · CDT: -61.51%
3M Horizon CDT +132.5 pp
ABVEW: -95.5% · CDT: +37.0%
6M Horizon CDT +40.08 pp
ABVEW: -96.84% · CDT: -56.76%
1Y Horizon CDT +48.39 pp
ABVEW: -96.95% · CDT: -48.56%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABVEW vs CDT. Trailing 12-month operating profitability (ABVEW N/A vs CDT 0.0%) and valuation multiples (ABVEW N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABVEW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CDT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABVEW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVEW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDT BREAKDOWN
163d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABVEW Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $507,528 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABVEW vs CDT Key Questions & Quantitative Answers

As of Nov 20, 2026, Above Food Ingredients Inc. Warrants (ABVEW) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 2–6 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ABVEW carries a Unified Composite Score of 37.2/100 (SELL) at $0.02 (N/M Forward P/E, N/A operating margin), whereas CDT carries 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although ABVEW compares more favorably head-to-head, both ABVEW (37.2/100 SELL) and CDT (31.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ABVEW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2); meanwhile CDT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDT leads the Growth & Scale pillar: ABVEW posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CDT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ABVEW generates N/A in USD-normalized revenue versus N/A for CDT. In operating R&D and SG&A reinvestment, ABVEW deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CDT.

ABVEW and CDT trade at balanced relative valuation multiples. ABVEW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CDT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABVEW (N/A ROE) versus CDT (-69.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ABVEW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.07β · 408% Vol realized risk). By comparison, CDT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (-17.75β · 10175% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.